Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Ascendis Pharma A (ASND) over the last 12 years, with Q3 2025 value amounting to $71.3 million.

  • Ascendis Pharma A's Profit After Tax rose 16544.77% to $71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.3 million, marking a year-over-year increase of 7550.01%. This contributed to the annual value of -$409.2 million for FY2024, which is 2100.22% up from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Profit After Tax is $71.3 million, which was up 16544.77% from -$44.0 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Profit After Tax high stood at $140.9 million for Q1 2022, and its period low was -$211.6 million during Q4 2022.
  • For the 5-year period, Ascendis Pharma A's Profit After Tax averaged around -$86.0 million, with its median value being -$108.9 million (2024).
  • In the last 5 years, Ascendis Pharma A's Profit After Tax tumbled by 25475.98% in 2021 and then surged by 16544.77% in 2025.
  • Over the past 5 years, Ascendis Pharma A's Profit After Tax (Quarter) stood at -$121.3 million in 2021, then plummeted by 74.41% to -$211.6 million in 2022, then skyrocketed by 55.83% to -$93.5 million in 2023, then skyrocketed by 56.02% to -$41.1 million in 2024, then skyrocketed by 273.45% to $71.3 million in 2025.
  • Its last three reported values are $71.3 million in Q3 2025, -$44.0 million for Q2 2025, and -$99.5 million during Q1 2025.